

Richard T Bryan Mbchb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8547378/publications.pdf>

Version: 2024-02-01

132
papers

3,615
citations

117571

34
h-index

149623

56
g-index

136
all docs

136
docs citations

136
times ranked

4573
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 1268-1277.	6.3	311
2	Detection of Intestinal Metaplasia in Barrett's Esophagus: An Observational Comparator Study Suggests the Need for a Minimum of Eight Biopsies. <i>American Journal of Gastroenterology</i> , 2007, 102, 1154-1161.	0.2	242
3	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	5.8	159
4	Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. <i>BJU International</i> , 2008, 101, 702-706.	1.3	156
5	Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. <i>International Journal of Epidemiology</i> , 2016, 45, 857-870.	0.9	148
6	Delay and survival in bladder cancer. <i>BJU International</i> , 2002, 89, 868-878.	1.3	138
7	The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imagingâ€“Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imagingâ€“Assisted TURBT in Primary Nonâ€“Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. <i>European Urology</i> , 2016, 70, 506-515.	0.9	122
8	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016, 24, 1167-1174.	1.4	115
9	Cadherin Switching and Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 423-431.	0.2	91
10	UroMarkâ€“a urinary biomarker assay for the detection of bladder cancer. <i>Clinical Epigenetics</i> , 2017, 9, 8.	1.8	81
11	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 301-317.	0.2	79
12	Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. <i>BMJ Open</i> , 2018, 8, e014530.	0.8	68
13	A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. <i>European Urology Oncology</i> , 2020, 3, 239-249.	2.6	67
14	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. <i>PLoS ONE</i> , 2016, 11, e0149756.	1.1	66
15	Mechanisms of recurrence of Ta/T1 bladder cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2010, 92, 519-524.	0.3	63
16	Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 407-407.	0.8	59
17	Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: <i>ex vivo</i> and <i>in vitro</i> studies. <i>Journal of Pathology</i> , 2008, 215, 184-194.	2.1	57
18	Centralisation of radical cystectomies for bladder cancer in England, a decade on from the â€“Improving Outcomes Guidanceâ€™: the case for super centralisation. <i>BJU International</i> , 2018, 121, 217-224.	1.3	54

#	ARTICLE	IF	CITATIONS
19	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010, 105, 784-788.	1.3	52
20	Targeted deep sequencing of urothelial bladder cancers and associated urinary <sc>DNA</sc>: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. <i>BJU International</i> , 2019, 124, 532-544.	1.3	47
21	Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140042.	1.8	46
22	Biomarkers in bladder cancer. <i>BJU International</i> , 2010, 105, 608-613.	1.3	44
23	Narrow-Band Imaging Flexible Cystoscopy: A New User's Experience. <i>Journal of Endourology</i> , 2010, 24, 1339-1343.	1.1	44
24	Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. <i>Journal of Urology</i> , 2016, 195, 872-879.	0.2	42
25	Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1854-1861.	2.9	41
26	Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. <i>European Journal of Cancer</i> , 2013, 49, 2214-2222.	1.3	41
27	Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0137003.	1.1	40
28	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228A>G/A/T Mutation. <i>Bladder Cancer</i> , 2018, 4, 41-48.	0.2	40
29	Frequency dependent viscoelastic properties of porcine bladder. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2015, 42, 168-176.	1.5	39
30	Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. <i>European Urology</i> , 2021, 80, 12-15.	0.9	38
31	The Role of β -Catenin Signaling in the Malignant Potential of Cystitis Glandularis. <i>Journal of Urology</i> , 2003, 170, 1892-1896.	0.2	37
32	Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. <i>British Journal of Cancer</i> , 2015, 112, 1052-1058.	2.9	36
33	Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. <i>Epigenetics</i> , 2016, 11, 237-246.	1.3	36
34	Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. <i>International Journal of Cancer</i> , 2013, 133, 446-454.	2.3	35
35	A comparison of patient and tumour characteristics in two <sc>UK</sc> bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013, 112, 169-175.	1.3	35
36	Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. <i>British Journal of Cancer</i> , 2014, 110, 679-685.	2.9	35

#	ARTICLE	IF	CITATIONS
37	â€œSuperficialâ€™ bladder cancer - time to uncouple pT1 tumours from pTa tumours. BJU International, 2002, 90, 846-852.	1.3	34
38	Molecular pathways in bladder cancer: Part 1. BJU International, 2005, 95, 485-490.	1.3	33
39	Liquid biopsies for bladder cancer. Translational Andrology and Urology, 2017, 6, 331-335.	0.6	33
40	Viscoelastic properties of human bladder tumours. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 61, 250-257.	1.5	32
41	Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. European Urology, 2019, 76, 258-259.	0.9	30
42	Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. Proteomics - Clinical Applications, 2011, 5, 493-503.	0.8	29
43	Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer. European Journal of Surgical Oncology, 2001, 27, 291-297.	0.5	28
44	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Scientific Reports, 2018, 8, 11290.	1.6	28
45	Molecular pathways in bladder cancer: Part 2. BJU International, 2005, 95, 491-496.	1.3	27
46	The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. Cancer Causes and Control, 2018, 29, 675-683.	0.8	23
47	The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Annals of the Royal College of Surgeons of England, 2014, 96, 415-419.	0.3	21
48	Bladder Cancer and Cancer Stem Cells: Basic Science and Implications for Therapy. Scientific World Journal, The, 2011, 11, 1187-1194.	0.8	18
49	Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. PLoS ONE, 2017, 12, e0184841.	1.1	18
50	Socio-economic deprivation and survival in bladder cancer. BJU International, 2004, 94, 539-543.	1.3	17
51	Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-GuÃ©rin. Future Oncology, 2014, 10, 1443-1456.	1.1	17
52	Axillary lipoblastomaâ€”tumor recurrence in the right atrium. Journal of Pediatric Surgery, 2003, 38, 1246-1247.	0.8	16
53	Health-related quality of life around the time of diagnosis in patients with bladder cancer. BJU International, 2019, 124, 984-991.	1.3	16
54	Emerging Endoscopic and Photodynamic Techniques for Bladder Cancer Detection and Surveillance. Scientific World Journal, The, 2011, 11, 2550-2558.	0.8	15

#	ARTICLE	IF	CITATIONS
55	So Much Cost, Such Little Progress. <i>European Urology</i> , 2014, 66, 263-264.	0.9	13
56	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1044-1051.	1.6	13
57	Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours. <i>Annals of the Royal College of Surgeons of England</i> , 2016, 98, 547-551.	0.3	12
58	Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 381-389.	2.6	12
59	Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. <i>Oncotarget</i> , 2018, 9, 25244-25253.	0.8	12
60	Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. <i>European Urology Oncology</i> , 2023, 6, 67-75.	2.6	12
61	HumanMethylation450K Array Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. <i>Biomarkers in Cancer</i> , 2018, 10, 1179299X1775192.	3.6	11
62	Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of V β 9/V α 2 T-Cell Immune Responses. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11258-11270.	2.9	11
63	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. <i>Frontiers in Oncology</i> , 2020, 10, 812.	1.3	11
64	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015, 1, 82-89.	1.6	10
65	Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. <i>Cancer Causes and Control</i> , 2018, 29, 573-579.	0.8	10
66	A Stratified Meta-Analysis of the Association between Exposure to Environmental Tobacco Smoke during Childhood and Adulthood and Urothelial Bladder Cancer Risk. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 569.	1.2	10
67	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2019, 5, 263-272.	0.2	10
68	Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. <i>European Urology Focus</i> , 2020, 6, 683-697.	1.6	10
69	Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. <i>International Journal of Cancer</i> , 2020, 147, 2091-2100.	2.3	10
70	The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11150.	1.8	10
71	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. <i>Future Oncology</i> , 2016, 12, 595-600.	1.1	9
72	Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study. <i>Bladder Cancer</i> , 2018, 4, 303-310.	0.2	7

#	ARTICLE	IF	CITATIONS
73	Patients choose certainty over burden in bladder cancer surveillance. <i>World Journal of Urology</i> , 2019, 37, 2747-2753.	1.2	7
74	Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1102.	1.8	7
75	Graham Roberts Study protocol: first â€”trials within cohort studyâ€™™ for bladder cancer. <i>BMJ Open</i> , 2019, 9, e029468.	0.8	7
76	Modeling the Complex Exposure History of Smoking in Predicting Bladder Cancer. <i>Epidemiology</i> , 2019, 30, 458-465.	1.2	7
77	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. <i>Translational Andrology and Urology</i> , 2021, 10, 2787-2808.	0.6	7
78	Optimising Existing Therapeutic Strategies for the Treatment of Nonâ€”Muscle-Invasive Bladder Cancer: The Role of Intensive Neoadjuvant Intravesical Mitomycin C. <i>European Urology</i> , 2012, 62, 803-805.	0.9	6
79	Gene-environment interaction with smoking for increased non- muscle-invasive bladder cancer tumor size. <i>Translational Andrology and Urology</i> , 2020, 9, 1329-1337.	0.6	6
80	Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators. <i>BJU Compass</i> , 2021, 2, 140-158.	0.7	6
81	PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium. <i>Frontiers in Oncology</i> , 2021, 11, 626748.	1.3	6
82	Immunotherapy for non-muscle-invasive bladderÂcancer: from the origins of BCG to novel therapies. <i>Future Oncology</i> , 2022, 18, 105-115.	1.1	6
83	Have We Abandoned the â€”Superficialâ€”in Bladder Cancer?. <i>European Urology</i> , 2009, 56, 1091.	0.9	5
84	Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. <i>Proteomes</i> , 2015, 3, 266-282.	1.7	5
85	The experience of UK patients with bladder cancer during the COVIDâ€”19 pandemic: a surveyâ€”based snapshot. <i>BJU International</i> , 2021, 127, 179-181.	1.3	5
86	Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?. <i>BMJ Open</i> , 2021, 11, e041894.	0.8	5
87	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Nonâ€”muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 70-83.	2.6	5
88	The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. <i>PLoS ONE</i> , 2021, 16, e0243136.	1.1	5
89	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 27-33.	0.6	5
90	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e346-e352.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. <i>Genome Medicine</i> , 2022, 14, .	3.6	5
92	Does the Nonurologic Scientific Community Understand Urothelial Bladder Cancer?. <i>European Urology</i> , 2014, 66, 601-602.	0.9	4
93	Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1989725.	3.6	4
94	Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical Utility. <i>European Urology</i> , 2020, 78, 538-539.	0.9	4
95	Editorial Comment on: A New Generation of Optical Diagnostics for Bladder Cancer: Technology, Diagnostic Accuracy, and Future Applications. <i>European Urology</i> , 2009, 56, 297.	0.9	3
96	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology & Men's Health</i> , 2015, 6, 23-27.	0.2	3
97	External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank. <i>Frontiers in Oncology</i> , 2019, 9, 1082.	1.3	3
98	Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer. <i>European Journal of Cancer Prevention</i> , 2019, 28, 40-44.	0.6	3
99	A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021, 7, 221-241.	0.2	3
100	Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. <i>BJU International</i> , 2021, , .	1.3	3
101	Multiplex screening of 422 candidate serum biomarkers in bladder cancer patients identifies syndecan-1 and macrophage colony-stimulating factor 1 as prognostic indicators. <i>Translational Cancer Research</i> , 2017, 6, S657-S665.	0.4	3
102	Massively parallel sequencing of urinary DNA—the dawn of non-invasive bladder cancer detection and surveillance?. <i>Translational Cancer Research</i> , 2019, 8, S204-S207.	0.4	3
103	Bladder cancer: time for a rethink?. <i>Oncology</i> , 2011, 25, 965, 968.	0.4	3
104	STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. <i>European Urology Open Science</i> , 2022, 38, 88-95.	0.2	3
105	Update on bladder cancer diagnosis and management. <i>Trends in Urology & Men's Health</i> , 2013, 4, 7-11.	0.2	2
106	Bladder Cancers Arise from Distinct Urothelial Sub-populations. <i>European Urology</i> , 2015, 67, 590-591.	0.9	2
107	MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation. <i>Bladder Cancer</i> , 2019, 5, 147-157.	0.2	2
108	Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions. <i>Cancer</i> , 2019, 125, 652-652.	2.0	2

#	ARTICLE	IF	CITATIONS
109	Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial. <i>Pilot and Feasibility Studies</i> , 2020, 6, 165.	0.5	2
110	Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?. <i>European Urology</i> , 2021, 80, 18-19.	0.9	2
111	Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience. <i>Inquiry (United States)</i> , 2021, 58, 004695802110302.	0.5	2
112	Primary Sternal Osteomyelitis in Infants. <i>Journal of Pediatric Orthopaedics Part B</i> , 1999, 8, 125-126.	0.3	1
113	Detection of Intestinal Metaplasia in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2007, 102, 2353-2354.	0.2	1
114	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014, 1, 176-183.	0.2	1
115	Re: Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. <i>Journal of Urology</i> , 2014, 191, 1930-1931.	0.2	1
116	Design of an improved surgical instrument for the removal of bladder tumours. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2016, 230, 579-587.	1.0	1
117	Urinary biomarkers for the diagnosis of urothelial bladder cancer. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 221.	0.5	1
118	Red patches during bladder cancer surveillance: to biopsy or not to biopsy?. <i>Translational Andrology and Urology</i> , 2018, 7, 280-282.	0.6	1
119	Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven MacLennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. <i>Eur Urol</i> 2019;76:260-1. <i>European Urology</i> , 2019, 76, e45-e46.	0.9	1
120	Asymptomatic Microscopic Haematuria and Significant Urinary Tract Disease. <i>Bladder Cancer</i> , 2019, 5, 115-117.	0.2	1
121	The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. <i>Trials</i> , 2020, 21, 629.	0.7	1
122	Establishing the Bladder Cancer Research Centre at the University of Birmingham. <i>Nature Reviews Urology</i> , 2021, 18, 318-320.	1.9	1
123	The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemic. <i>BJU Compass</i> , 0, , .	0.7	1
124	IS IT TIME TO REDESIGN THE HAEMATURIA CLINIC?. <i>BJU International</i> , 2010, 105, 1478-1479.	1.3	0
125	Re: Palou et al.: Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors. (<i>Urology</i> 2009;73:1313-1317). <i>Urology</i> , 2009, 74, 714.	0.5	0
126	NARROW BAND IMAGING FLEXIBLE CYSTOSCOPY: AN UPDATE AND A NEW USER'S EXPERIENCE. <i>Journal of Urology</i> , 2009, 181, 415-415.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Editorial Comment on: Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland. <i>European Urology</i> , 2010, 57, 496-497.	0.9	0
128	Ciprofloxacin Resistance in the Faecal Carriage of Patients Undergoing Transrectal Ultrasound Guided Prostate Biopsy. <i>European Urology</i> , 2015, 67, 591-592.	0.9	0
129	Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. <i>European Journal of Cancer Prevention</i> , 2020, 29, 110-118.	0.6	0
130	Festschrift in Honor of Professor Margaret Anne Knowles. <i>Bladder Cancer</i> , 2020, 6, 537-548.	0.2	0
131	Urinary EGFR as a marker of urinary bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 327-327.	0.8	0
132	Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?. <i>BMJ Open</i> , 2022, 12, e049241.	0.8	0